SCHEMBL20873283

SCHEMBL20873283

C#CCCCCCCNC(=O)C1O[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@@H](OC(C)=O)[C@@H]1OC(C)=O

nearest known ligand 0.35

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ OGA O60502 1/20 0.35
▸ MEN1 O00255 1/20 0.34
▸ USP2 O75604 1/20 0.34
▸ ALDH1A1 P00352 1/20 0.34
▸ TP53 P04637 1/20 0.34
▸ CYP3A4 P08684 1/20 0.34
▸ MAPT P10636 1/20 0.34
▸ MAPK1 P28482 1/20 0.34
▸ KMT2A Q03164 1/20 0.34
▸ CA12 O43570 3/20 0.32
▸ CA1 P00915 3/20 0.32
▸ CA2 P00918 3/20 0.32
▸ CA9 Q16790 3/20 0.32
▸ CYP2D6 P10635 1/20 0.30
▸ THRB P10828 1/20 0.30
▸ HSD17B10 Q99714 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21112943 0.87 OGA (0.32) OGAMEN1USP2ALDH1A1TP53
SCHEMBL14172398 0.81 CA2 (0.38) OGACA12CA1CA2CA9
SCHEMBL15927259 0.81 CA2 (0.38) OGACA12CA1CA2CA9
SCHEMBL13944663 0.81 CA2 (0.38) OGACA12CA1CA2CA9
SCHEMBL21113007 0.80 OGA (0.32) OGA
SCHEMBL23740239 0.71 CA9 (0.34) OGACA12CA1CA2CA9
SCHEMBL22328424 0.71 OGA (0.33) OGACA12CA1CA2CA9
SCHEMBL15927229 0.71 OGA (0.33) OGACA12CA1CA2CA9
SCHEMBL15927395 0.68 CA9 (0.38) CA12CA1CA2CA9
SCHEMBL20873287 0.68 CYP1A2 (0.34) ALDH1A1MAPTCYP2D6HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210401946-A1 CONJUGATES OF A PHARMACEUTICAL AGENT AND A MOIETY CAPABLE OF BINDING TO A GLUCOSE SENSING PROTEIN SANOFI (FR) 2021-12-30 — — US disclosed
US-20210401946-A1 CONJUGATES OF A PHARMACEUTICAL AGENT AND A MOIETY CAPABLE OF BINDING TO A GLUCOSE SENSING PROTEIN SANOFI (FR) 2021-12-30 — — US disclosed
US-20210401947-A1 CONJUGATES OF A PHARMACEUTICAL AGENT AND A MOIETY CAPABLE OF BINDING TO A GLUCOSE SENSING PROTEIN SANOFI (FR) 2021-12-30 — — US disclosed
US-11090364-B2 Conjugates of a pharmaceutical agent and a moiety capable of binding to a glucose sensing protein SANOFI (FR) 2021-08-17 — — US disclosed
US-20190209656-A1 CONJUGATES OF A PHARMACEUTICAL AGENT AND A MOIETY CAPABLE OF BINDING TO A GLUCOSE SENSING PROTEIN SANOFI (FR) 2019-07-11 — — US disclosed
EP-3463480-A1 CONJUGATES OF A PHARMACEUTICAL AGENT AND A MOIETY CAPABLE OF BINDING TO A GLUCOSE SENSING PROTEIN Sanofi (FR) 2019-04-10 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11090364-B2 Conjugates of a pharmaceutical agent and a moiety capable of binding to a glucose sensing protein GPR119, SLC2A8, SLC2A4 OGA 131/4885MEN1 1610/4885USP2 2506/4885
US-20190209656-A1 CONJUGATES OF A PHARMACEUTICAL AGENT AND A MOIETY CAPABLE OF BINDING TO A GLUCOSE SENSING PROTEIN GPR119, SLC2A8, SLC2A4 OGA 131/4885MEN1 1610/4885USP2 2506/4885
US-20210401946-A1 CONJUGATES OF A PHARMACEUTICAL AGENT AND A MOIETY CAPABLE OF BINDING TO A GLUCOSE SENSING PROTEIN GPR119, SLC2A8, SLC2A4 OGA 131/4885MEN1 1610/4885USP2 2506/4885
US-20210401947-A1 CONJUGATES OF A PHARMACEUTICAL AGENT AND A MOIETY CAPABLE OF BINDING TO A GLUCOSE SENSING PROTEIN GPR119, SLC2A8, SLC2A4 OGA 131/4885MEN1 1610/4885USP2 2506/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback